Who are rivaroxaban and ticagrel therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rivaroxaban-and-ticagrel-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

rivaroxaban and ticagrel therapy — Competitive Intelligence Brief

rivaroxaban and ticagrel therapy (rivaroxaban and ticagrel therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant and antiplatelet combination therapy. Area: Cardiovascular.

marketed Anticoagulant and antiplatelet combination therapy Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

rivaroxaban and ticagrel therapy (rivaroxaban and ticagrel therapy) — Beijing Anzhen Hospital. Rivaroxaban and ticagrelor together provide dual anticoagulation and antiplatelet therapy to prevent thrombotic events.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rivaroxaban and ticagrel therapy TARGET	rivaroxaban and ticagrel therapy	Beijing Anzhen Hospital	marketed	Anticoagulant and antiplatelet combination therapy	Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant and antiplatelet combination therapy class)

Beijing Anzhen Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rivaroxaban and ticagrel therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/rivaroxaban-and-ticagrel-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab